Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! CATALYST BIOSCIENCES Nasdaq: CBIO catalystbiosciences.com 3 Catalyst Biosciences: CBIO We are working to establish a new standard of care in hemophilia prophylaxis by developing highly potent subcutaneous treatments that improve the quality of life for patients with hemophilia with inhibitors, acquired hemophilia & hemophilia B CBIO Interactive Stock Chart | Catalyst Biosciences, Inc ... At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
CBIO - Catalyst Bio Stock Interactive Chart - Barchart.com
CATALYST BIOSCIENCES Nasdaq: CBIO catalystbiosciences.com 3 Catalyst Biosciences: CBIO We are working to establish a new standard of care in hemophilia prophylaxis by developing highly potent subcutaneous treatments that improve the quality of life for patients with hemophilia with inhibitors, acquired hemophilia & hemophilia B CBIO Interactive Stock Chart | Catalyst Biosciences, Inc ... At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. CBIO stock: Catalyst Biosciences Inc Catalyst Biosciences Inc's stock rating is based on fundamental analysis. Don't miss CBIO stock next rating changes
ST Invest LLC (d/b/a Trade App) is a wholly owned subsidiary of StockTwits, Inc. Securities products and services offered to self-directed investors through ST Invest LLC. ST Invest LLC is a member of the Financial Industry Regulatory Authority (FINRA)
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. Catalyst Biosciences, Inc. - CBIO - Stock Price Today - Zacks View Catalyst Biosciences, Inc. CBIO investment & stock information. Get the latest Catalyst Biosciences, Inc. CBIO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. CBIO Stock Price and Chart — NASDAQ:CBIO — TradingView cbio has been popping up multiple times on my scans playing around in my action zone between the 10ma and 30ema with 5 consecutive down days + nr7 inside day on low volume. Looks to be holding those supports quite well, triangulating and Volume has been drying up nicely.
Catalyst Biosciences, Inc. (CBIO) Stock Forum & Discussion ...
CBIO: Catalyst Biosciences, Inc. - Interactive Chart Chart. Get the latest Interactive Chart for Catalyst Biosciences, Inc. from Zacks Investment Research Why Catalyst Biosciences Inc. (CBIO) Stock Tripled on ... Mar 28, 2017 · Why Catalyst Biosciences Inc (CBIO) Stock Tripled on Tuesday INDA approval sends CBIO stock through the roof By Robert Martin , InvestorPlace … CBIO Price Target and Analyst Ratings (Catalyst Biosciences) Nov 05, 2019 · 1 Wall Street analysts have issued ratings and price targets for Catalyst Biosciences in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 514.25%. The high price target for CBIO is … CBIO - Catalyst Bio Stock Interactive Chart - Barchart.com Chart Size: Identifies the overall height of the chart on the page.Choose from Small, Medium, Large, X-Large. Navigator: The "Navigator" is a small series that appears below the chart axis, displaying a view of the entire data set.Use it as a tool to zoom in and out the time-line, or to pan across the dataset.
CBIO -- Is Its Stock Price A Worthy Investment? Learn More.
CBIO updated stock price target summary. Dow Jones, a News Corp company. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Press Releases | Catalyst Biosciences, Inc.